← 返回

急性髓系白血病中的 CAR-NK 细胞治疗:当前治疗、挑战与优势

英文原题:CAR-NK cell therapy in AML: Current treatment, challenges, and advantage.

查看英文原题

CAR-NK cell therapy in AML: Current treatment, challenges, and advantage.

PubMed 2024/06/27(内容时间) Biomed Pharmacother

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

过去十年,新型治疗方法的发现改变了血液恶性肿瘤治疗格局。NK细胞可清除异常及癌变细胞,但在血液恶性肿瘤中可能发生功能失常。CAR-NK疗法通过工程化NK细胞识别肿瘤特异性抗原并清除癌细胞,在多种恶性肿瘤中展现临床应用优势。本文综述NK细胞功能障碍及CAR-NK免疫疗法在急性髓系白血病治疗中的应用。

展开英文摘要原文

Over the last decade, discovery of novel therapeutic method has been attention by the researchers and has changed the therapeutic perspective of hematological malignancies. Although NK cell play a pivotal role in the elimination of abnormal and cancerous cells, there are evidence that NK cell are disarm in hematological malignancy.

Chimeric antigen receptor NK (CAR-NK) cell therapy, which includes the engineering of NK cells to detect tumor-specific antigens and, as a result, clear of cancerous cells, has created various clinical advantage for several human malignancies treatment. In the current review, we summarized NK cell dysfunction and CAR-NK cell based immunotherapy to treat AML patient.

论文信息

作者
Bahramloo M、Shahabi SA、Kalarestaghi H、Rafat A、Mazloumi Z、Samimifar A、Asl KD
第一作者单位
Department of Medical Sciences, Student Research Committee, Islamic Azad University, Tabriz Branch, Tabriz, Iran.Iran
通讯作者单位
Department of Histopathology and Anatomy, Faculty of Medical Sciences, Tabriz Medical Sciences, Islamic Azad University, Tabriz, Iran. Electronic address: kh.asli2013@gmail.com.Iran
文献类型
综述
期刊
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2024 Aug
原文标识
PubMed 38941897 · DOI 10.1016/j.biopha.2024.117024